MedTrace Logo

Study on Colonic Fermentation in Chronic Kidney Disease Patients

NCT01874210 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2016-05-18

No results posted yet for this study

Summary

Chronic kidney disease is associated with the accumulation of various metabolites, i.e., uremic retention solutes. Evidence is mounting that the colonic microbiome contributes substantially to these uremic retention solutes. Indoxyl sulfate and p-cresyl sulfate are among the most extensively studied gut microbial metabolites, and are associated with cardiovascular disease, chronic kidney disease progression and overall mortality. Indirect findings suggest that chronic kidney disease influences the colonic microbial metabolism with higher p-cresyl sulfate urinary excretion rates at more advanced renal disease. Therefore, this study aims to elucidate the influence of renal dysfunction on microbial metabolism and to test the hypothesis that chronic kidney disease patients carry a different fecal metabolite profile.

Conditions

  • Renal Insufficiency, Chronic

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Ruben Poesen, MD · Universitaire Ziekenhuizen KU Leuven

  • Björn Meijers, MD, PhD · Universitaire Ziekenhuizen KU Leuven

  • Kristin Verbeke, Pharm PhD · Universitaire Ziekenhuizen KU Leuven

  • Pieter Evenepoel, MD, PhD · Universitaire Ziekenhuizen KU Leuven

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874210 on ClinicalTrials.gov